Get the Stockscreener App
5.19
5.70%
0.28
After Hours:
5.09
-0.10
-1.93%
Myriad Genetics Inc stock is traded at $5.19, with a volume of 1.25M.
It is up +5.70% in the last 24 hours and up +11.37% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$4.91
Open:
$4.85
24h Volume:
1.25M
Relative Volume:
0.77
Market Cap:
$485.31M
Revenue:
$824.50M
Net Income/Loss:
$-365.90M
P/E Ratio:
-1.3129
EPS:
-3.9531
Net Cash Flow:
$-25.60M
1W Performance:
+8.81%
1M Performance:
+11.37%
6M Performance:
-35.93%
1Y Performance:
-35.21%
1-Day Range:
$4.85
$5.36
1-Week Range:
$4.31
$5.36
52-Week Range:
$3.76
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.19 | 459.13M | 824.50M | -365.90M | -25.60M | -3.9531 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad (MYGN) up 4.1% since last earnings report: Can it continue? - MSN
Myriad Genetics (NASDAQ: MYGN) sets 2026 votes and outlines cancer-focused growth - Stock Titan
Myriad Genetics Expands MyChoice Test Access for Prostate Cancer Patients in Japan - National Today
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - Bitget
Japan clears Myriad test for prostate cancer patients using Lynparza - Stock Titan
GeneCentric to Present Data on Fragmentomics-Based ExpressCT™ Liquid Biopsy Technology at AACR 2026 - Yahoo Finance
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y - MSN
Sectors Review: What is the next catalyst for Myriad Genetics IncPortfolio Return Report & Low Risk High Reward Ideas - baoquankhu1.vn
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Lobbying Update: $30,000 of TIBER CREEK GROUP ON BEHALF OF MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting - ChartMill
Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Trend Report: Can Myriad Genetics Inc maintain its current growth rate2026 Opening Moves & Long Hold Capital Preservation Tips - baoquankhu1.vn
Market Outlook: Whats next for Myriad Genetics Inc stockMarket Trend Report & AI Optimized Trade Strategies - baoquankhu1.vn
MYGN Technical Analysis | Trend, Signals & Chart Patterns | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance UK
Myriad Genetics | SCHEDULE 13G/A: Others - Moomoo
BlackRock (NYSE: MYGN) holds 7.98M shares, 8.5% stake reported - Stock Titan
Myriad Genetics Q4 2025 Results: Revenue Beat, Raised GuidanceNews and Statistics - IndexBox
Myriad Genetics And 2 Other Penny Stocks To Watch Closely - Yahoo Finance
Myriad Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics: Market Pricing in Failure as Catalysts Build for Re-Rating - Bitget
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Myriad Genetics Inc (MYD.HA) Stock Price, News, Quote & History - ca.finance.yahoo.com
3 Healthcare Stocks with Open Questions - Yahoo Finance
Myriad Genetics: SOTP Suggests The Company Is Undervalued - Seeking Alpha
Myriad Genetics, Inc. (MYD.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance
Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union
Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan
Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan
Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P Composite 1500 - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 Health Care - marketscreener.com
Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000 - marketscreener.com
If You Invested $1,000 in Myriad Genetics (MYGN) - Stock Titan
Gene Patent Showdown For Myriad Comes to a Head - Yahoo
MYGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Myriad Genetics Inc Stock (MYGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):